Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Di Rocco

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Leukemia & Lymphoma|October 9, 2021
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana LinfomiAnnalisa Arcari, Lucia Morello, Daniele Vallisa, et al.
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Transplantation and Cellular Therapy|January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE StudyFederico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Transplantation and Cellular Therapy|February 25, 2026
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE StudyAngelica Barone, Federico Stella, Silva Ljevar, et al.
Blood Cancer Discovery|July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell LymphomasFederico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Leukemia & Lymphoma|October 9, 2021
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana LinfomiAnnalisa Arcari, Lucia Morello, Daniele Vallisa, et al.
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Transplantation and Cellular Therapy|January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE StudyFederico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Transplantation and Cellular Therapy|February 25, 2026
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE StudyAngelica Barone, Federico Stella, Silva Ljevar, et al.
Blood Cancer Discovery|July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell LymphomasFederico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Pageof 11